Ignite Creation Date:
2025-12-25 @ 4:08 AM
Ignite Modification Date:
2026-01-28 @ 11:52 PM
Study NCT ID:
NCT02204020
Status:
WITHDRAWN
Last Update Posted:
2018-03-30
First Post:
2014-07-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
Sponsor:
University of Pittsburgh
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Acute Myeloid Leukemia (AML) | View |
| None | Myelodysplastic Syndrome (MDS) | View |
| None | allogeneic | View |
| None | 5-azacytidine (5-aza) | View |
| None | hematopoietic | View |
| None | transplantation | View |
| None | transplant | View |
| None | graft-versus-tumor | View |
| None | graft-versus-host disease (GVHD) | View |
| None | epigenetic | View |
| None | maintenance | View |
| None | hypomethylation | View |
| None | relapse | View |